The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.